10 completed, 9 recruiting, 9 terminated, 5 active not recruiting. 10 Not applicable, 10 Phase 2, 7 Phase 1, 4 Phase 3, 2 Early Phase 1.
Follow Bladder Carcinoma: new trials by email Literature Review of Bladder Carcinoma trials Research Report on Bladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tumor Budding and T1 Substaging in Urothelial Bladder Cancer Urothelial Bladder Carcinoma, Bladder Carcinoma | Not yet recruiting | Assiut University | 100 | 2026-05-01 | 2026-04-14 | |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment - Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy | Phase 3 | Recruiting | University of Rome Tor Vergata | 92 | 2025-08-15 | 2025-07-24 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| The Vanguard Study: Testing a New Way to Screen for Cancer Biospecimen Collection, Device Usage, Electronic Health Record Review - Bladder Carcinoma, Breast Carcinoma | Not applicable | Recruiting | National Cancer Institute (NCI) | 24000 | 2025-06-18 | 2026-10-06 |
| Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy Non-Interventional Study - Bladder Carcinoma | Recruiting | Mayo Clinic | 300 | 2025-01-15 | 2026-08-11 | |
| PET-imaging of Two Vartumabs in Patients With Solid Tumors 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan - Solid Tumor, Colon Carcinoma | Early Phase 1 | Recruiting | Var2 Pharmaceuticals | 32 | 2024-12-10 | 2025-12-29 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| Vaccine Response With NT-I7 Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2 - Breast Carcinoma, Colorectal Adenocarcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2023-05-30 | 2023-11-02 | |
| Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics Blood and Tissue - Bladder Cancer, Prostate Cancer | Terminated | Mayo Clinic | 13 | 2023-04-19 | 2025-04-27 | |
| Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers Best Practice, Bright White Light Therapy, Occupational Therapy - Bladder Carcinoma, Genitourinary System Neoplasm | Not applicable | Recruiting | City of Hope Medical Center | 224 | 2023-01-11 | 2026-10-19 |
| EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy Prehabilitation - Bladder Carcinoma | Not applicable | Unknown | The Netherlands Cancer Institute | 154 | 2022-08-11 | 2022-10-31 |
| Bladder Bank (a Prospective Banking Study) Non-Interventional Study - Bladder Carcinoma | Recruiting | Mayo Clinic | 1500 | 2022-07-06 | 2026-10-14 | |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab - Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Fusion Pharmaceuticals Inc. | 6 | 2022-04-20 | 2023-12-19 |
| Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device CATUVAB - Bladder Carcinoma, Prostate Tumor | Not applicable | Completed | Lindis Bloodcare GmbH | 136 | 2022-02-15 | 2025-01-23 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation Guardant Reveal - Bladder Carcinoma, Ureter Carcinoma | Recruiting | Guardant Health, Inc. | 2285 | 2021-09-07 | 2026-09-14 | |
| Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Clindamycin, Diary, Ertapenem - Bladder Carcinoma, Refractory Bladder Carcinoma | Phase 4 | Completed | Roswell Park Cancer Institute | 89 | 2020-09-02 | 2026-09-29 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography - Bladder Carcinoma, Cervical Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 26 | 2020-08-27 | 2026-02-05 |
| Patient-Derived Xenografts to Reduce Cancer Health Disparities Biospecimen Collection - Bladder Carcinoma, Gastric Carcinoma | Recruiting | University of California, Davis | 500 | 2019-11-12 | 2026-08-20 | |
| hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" Cabozantinib, Durvalumab - Bladder Carcinoma | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 122 | 2019-09-25 | 2021-02-25 |
Showing 20 of 40. Sign in to see all of them.
Urinary Bladder Neoplasms (40) · Breast Neoplasms (10) · Lung Neoplasms (10) · Colorectal Neoplasms (9) · Prostatic Neoplasms (9) · Carcinoma, Hepatocellular (8) · Carcinoma, Renal Cell (8) · Colonic Neoplasms (7) · Melanoma (7) · Ovarian Neoplasms (7) · Pancreatic Neoplasms (7) · Stomach Neoplasms (7) · Esophageal Neoplasms (6) · Carcinoma, Transitional Cell (5) · Neoplasms (5)
Female Urogenital Diseases (40) · Female Urogenital Diseases and Pregnancy Complications (40) · Male Urogenital Diseases (40) · Neoplasms by Site (40) · Urogenital Diseases (40) · Urinary Bladder Diseases (39) · Urogenital Neoplasms (39) · Urologic Diseases (39) · Urologic Neoplasms (39) · Neoplasms (35) · Neoplasms by Histologic Type (21) · Neoplasms, Glandular and Epithelial (20) · Carcinoma (19) · Digestive System Diseases (16) · Digestive System Neoplasms (16)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (3) · Cystoscopy (2) · FAPI-46 (2) · Fluorodeoxyglucose F18 (2) · erdafitinib (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Alloderm (1) · Antineoplastic Protocols (1) · Biopsy (1) · Blood Specimen Collection (1)
Mayo Clinic (5) · National Cancer Institute (NCI) (5) · City of Hope Medical Center (3) · Jonsson Comprehensive Cancer Center (2) · University Hospital, Bordeaux (2) · University of Southern California (2) · University of Washington (2) · AHS Cancer Control Alberta (1) · Assiut University (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fusion Pharmaceuticals Inc. (1) · Guardant Health, Inc. (1) · Lindis Bloodcare GmbH (1) · Matthew Galsky (1) · Merck Sharp & Dohme LLC (1)
United States (26) · France (3) · Italy (3) · Canada (2) · Germany (2) · Netherlands (2) · Australia (1) · China (1) · Guam (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Jeremie Calais (2) · Adrian S Ishkanian, MD (1) · Bethan Phillips, BSc PhD (1) · Di Maria Jiang (1) · Don Yee, MD (1) · Gooitzen van Dam, MD, PhD (1) · Hooman Djaladat (1) · Jill M Hamilton-Reeves (1) · Jing Zeng (1) · John B. Kisiel, MD (1) · John Williams, MBChB PhD (1) · Jon Lund, MD (1) · Jonathan Wright (1)
PMID 10673991, PMID 16773629, PMID 17997439, PMID 19097774, PMID 21555688, PMID 23770567, PMID 24472710, PMID 24476821, PMID 25428503, PMID 26487582, PMID 26586415, PMID 27140411, PMID 27269937, PMID 27324051, PMID 27345655, PMID 27726966, PMID 28078238, PMID 28271869, PMID 28481359, PMID 28817753, PMID 32000810, PMID 32463741, PMID 32620210, PMID 33048619, PMID 34006499, PMID 35133871, PMID 35138919, PMID 35438782, PMID 36351402, PMID 36882246, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38620056, PMID 38986134, PMID 39187984, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40279497, PMID 40865033, PMID 41066729, PMID 42475098, PMID 42571808
P30CA015704 (3), P30CA014089 (2), 2017 (1), N01CN00033 (1), P30CA014520 (1), P30CA033572 (1), P30CA093373 (1), R44CA192588 (1), U10CA180820 (1), U24CA196172 (1), U54CA233306 (1), UG1CA189974 (1), UG1CA286954 (1), UM1CA186644 (1)